Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
2期
已完成
NCT06350123
| 适应症 | Chronic Kidney Disease |
|---|
| 分期 | 2期 |
|---|
| 申办方 | AstraZeneca |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 324 人 |
|---|
| 干预(药物) | Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin |
|---|
| 开始日期 | 2024年5月1日 |
|---|
| 完成日期 | 2025年5月9日 |
|---|
| 结果公布日 | 2026年6月26日 |
|---|
摘要
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.
Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12
Baseline (Day 1) until Week 12 (Day 85) · mg/g
| Balcinrenone/Dapagliflozin 15 mg/10 mg | 0.76 mg/g |
|---|
| Balcinrenone/Dapagliflozin 40 mg/10 mg | 0.66 mg/g |
|---|
| Dapagliflozin 10 mg | 0.98 mg/g |
|---|
| p-value | <0.001 |
| Percent change difference | -32.77 (95% CI -41.96–-22.14) |
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。